Several U.S. senators have asked the Health and Human Services Department to explain what, if any, steps are being taken to ensure that patents held by the federal government on an HIV prevention pill are properly licensed. The lawmakers also asked agency officials to demonstrate how they take into account whether medicines are affordable when considering licensing patents.

The move comes as AIDS activists have criticized the Centers for Disease Control and Prevention for failing to reach a deal with Gilead Sciences (GILD) over royalties on its sales of the Truvada pill. The activists complain that a high price has dissuaded people from using the drug and hope any funds that could become available from royalties would be used for combating the virus.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy